



## Day 1 – 13 November 2020

- 12:40 – 12:45 Welcome and Introduction** Virtual Room 1  
Medical oncologist - Aristotelis Bamias, Athens (GR)  
Radiation oncologist - Peter Hoskin, Northwood (GB)  
Urologist - Arnulf Stenzl, Tübingen (DE)
- 12:45 – 13:30 Individualised approaches in advanced prostate cancer**  
Chairs: Medical oncologist - Jan Oldenburg, Oslo (NO)  
Radiation oncologist - Thomas Zilli, Geneva (CH)  
Urologist - Jochen Walz, Marseille (FR)
- 12:45 – 12:55 Germline mutation testing: When and how?**  
Medical oncologist - Johann De Bono, Sutton (GB)
- 12:55 – 13:05 PSMA PET for upfront staging in high risk disease?**  
Urologist - Declan Murphy, Melbourne (AU)
- 13:05 – 13:15 Who is the optimal candidate for treatment of the primary tumour in oligometastatic disease?**  
Radiation oncologist - Piet Ost, Ghent (BE)
- 13:15 – 13:30 Discussion**
- 13:30 – 13:45 Industry presentation** Virtual Room 1
- 13:45 – 14:30 Metastatic prostate cancer** Virtual Room 2  
Chairs: Radiation oncologist - Peter Hoskin, Northwood (GB)  
Medical oncologist - Silke Gillessen, Bellinzona (CH)  
Urologist - Hein Van Poppel, Leuven (BE)
- Multidisciplinary case discussion: Metachronous metastatic prostate cancer**  
Case presenter: Urologist - Giorgio Gandaglia, Milan (IT)  
Case discussants: Medical oncologist - Silke Gillessen, Bellinzona (CH)  
Pathologist - Antonio Lopez-Beltran, Lisbon (PT)  
Radiation oncologist - Gert De Meerleer, Leuven (BE)  
Radiologist - Raymond Oyen, Leuven (BE)  
Urologist - Markus Graefen, Hamburg (DE)
- 14:30 – 14:45 Industry presentation** Virtual Room 2

<b>14:45 – 15:30</b>	<b>Highlights in GU cancers</b> Chairs: Medical oncologist – Stephane Oudard, Paris (FR) Pathologist - Rodolfo Montironi, Ancona (IT) Urologist - Morgan Rouprêt, Paris (FR)	Virtual Room 1
<b>14:45 – 14:55</b>	<b>ESUP lecture: Highlights from the Genito-Urinary Pathology Society (GUPS)</b> Pathologist - Jonathan Epstein, Baltimore (US)	
<b>14:55 – 15:05</b>	<b>The EAU research foundation: Trials in progress</b> Urologist - Anders Bjartell, Malmö (SE)	
<b>15:05 - 15:15</b>	<b>Highlights in Europa Uomo Patient Reported Outcomes Study (EUPROMS)</b> Patient Advocate – André Deschamps, Antwerp (BE)	
<b>15:15 – 15:30</b>	<b>Discussion</b>	
<b>15:30 – 15:45</b>	<b>Industry presentation</b>	Virtual Room 1
<b>15:45 – 16:30</b>	<b>Refining the treatment of bladder cancer</b> Chairs: Medical oncologist - Andrea Necchi, Milan (IT) Pathologist - Eva Compérat, Paris (FR) Urologist - George Thalmann, Berne (CH)	Virtual Room 2
<b>15:45 – 15:55</b>	<b>Novel options for the treatment of high risk non-muscle bladder cancer</b> Urologist - Marc-Oliver Grimm, Jena (DE)	
<b>15:55 – 16:05</b>	<b>Molecular sub-staging: Is it really useful?</b> Urologist - Peter Black, Vancouver (CA)	
<b>16:05 – 16:15</b>	<b>Optimal first line therapy in metastatic disease</b> Medical oncologist - Matthew Galsky, New York (US)	
<b>16:15 – 16:30</b>	<b>Discussion</b>	
<b>16:30 – 17:15</b>	<b>Industry session Janssen</b>	Virtual Room 1
<b>17:15 – 18:00</b>	<b>Round table on the Impact of COVID-19 epidemic on the management of GU cancers</b> Chairs: Medical oncologist - Aristotelis Bamias, Athens (GR) Radiation oncologist - Carl Salembier, Brussels (BE) Urologist - Arnulf Stenzl, Tübingen (DE)	Virtual Room 2
<b>17:15 – 17:25</b>	<b>Does the Corona infection interfere with immune status of oncological patients?</b> Virologist - TBC	
<b>17:25 – 17:35</b>	<b>Impact on COVID-19 on treatments of GU cancers</b> Urologist - Christopher Wallis, Nashville (US)	
<b>17:35 – 17:45</b>	<b>Indications from the EAU Guidelines Office Rapid Reaction Group (GORRG)</b> Urologist - Maria Ribal, Barcelona (ES)	
<b>17:45 – 18:00</b>	<b>Discussion</b>	
<b>18:00 – 18:45</b>	<b>Industry session</b>	Virtual Room 1
<b>18:45 – 19:30</b>	<b>New trials update</b> Chairs: Medical oncologist - Silke Gillessen, Bellinzona (CH) Radiation oncologist - Jean Emmanuel Bibault, Paris (FR) Urologist - Bertrand Tombal, Brussels (BE)	

**18:45 – 19:00** **PROFOUND**

Speaker: Medical oncologist - Maha Hussain, Ann Arbor (US)

Discussant: Medical oncologist – Henrik Gronberg, Stockholm (SW)

**19:00 – 19:15** **NIMBUS Trial**

Speaker: Urologist - Marc Oliver Grimm, Jena (DE)

Discussant: Urologist - Axel Merseburger, Lübeck (DE)

**19:15 – 19:30** **DANUBE Trial**

Speaker: Medical oncologist - Thomas Powles, London (GB)

Discussant: Medical oncologist - Andrea Necchi, Milan (IT)

**19:30 – 20:15** **Multidisciplinary case discussion on kidney cancer**

Virtual Room 2

Chairs: Medical oncologist - Laurence Albiges, Villejuif (FR)

Pathologist - TBC

Urologist - Igle Jan De Jong, Groningen (NL)

Radiation oncologist - Michael Pinkawa, Bonn (DE)

**19:30 – 20:15** **Intermediate risk metastatic renal cell cancer**

Case presenter: Urologist - Carme Mir, Barcelona (ES)

Discussants: Urologist - Axel Bex, London (GB)

Urologist - Michael Staehler, Munich (DE)

Medical oncologist - Laurence Albiges, Villejuif (FR)

Medical oncologist - Camillo Porta, Bari (IT)

Radiation oncologist - Michael Pinkawa, Bonn (DE)



## Day 2 – 14 November 2020

- 12:00 - 12:45**    **Neoadjuvant versus adjuvant strategies in locally advanced bladder cancer**    Virtual Room 1  
 Chairs: Urologist - George Thalmann, Berne (CH)  
 Medical oncologist - Thomas Powles, London (GB)
- 12:00 – 12:05    Case presenter: Urologist - Marco Moschini, Lucerne (CH)  
 12:05 – 12:15    **Neoadjuvant strategies** discussant: Medical oncologist - Andrea Necchi, Milan (IT)  
 12:15 – 12:25    **Adjuvant strategies** discussant: Urologist - Maria Ribal, Barcelona (ES)  
 12:25 - 12:45    Discussion
- 12:45 – 13:30**    **Multi-disciplinary case discussion on testicular cancer**    Virtual Room 2  
 Chair: Medical oncologist - Christoph Oing, Hamburg (DE)
- Case presenter: Medical oncologist - Christoph Oing, Hamburg (DE)  
 Discussants:    Urologist - Axel Heidenreich, Cologne (DE)  
                     Medical oncologist - Jan Oldenburg, Oslo (NO)  
                     Radiation oncologist - Gert De Meerleer, Leuven (BE)  
                     Radiologist - TBC
- 13:30 – 13:45**    **Industry presentation**    Virtual Room 2
- 13:45 – 14:30**    **Fragments of imaging**    Virtual Room 1  
 Chairs: Urologist - Georg Salomon, Hamburg (DE)  
           Urologist - Francesco Sanguedolce, Barcelona (ES)
- 13.45 – 13.52    **Multiparametric MRI changed the world of PCa diagnostic**  
**From conventional MRI to spectroscopy to mpMRI back to just DWI?**  
 Radiologist - Jurgen Futterer, Nijmegen (NL)
- 13.52 – 13.59    **Ultrasound is improving 29 Mhz, mpUS, C-TRUS, Elastography and microbubbles**  
 Urologist - Christophe Mannaerts, Amsterdam (NL)
- 13.59 – 14.06    **The rising star: PET CT beyond PSMA**  
**What you might not know about different & upcoming tracers**  
 Nuclear medicine - Frederik Giesel, Heidelberg (DE)
- 14.06 – 14.13    **Nanoparticles: A perspective for the future**  
 Radiologist - Jelle Barentsz, Nijmegen (NL)
- 14.13 – 14.20    **Virads – Can we avoid TUR-B prior to radical cystectomy?**  
 Radiologist - Valeria Panebianco, Rome (IT)
- 14.20 – 14.30    Discussion

<b>14:30 – 14:45</b>	<b>Industry presentation</b>	Virtual Room 1
<b>14:45 – 15:30</b>	<b>Oral presentation of the 6 best abstracts</b> Chairs: Urological researcher - Kerstin Junker, Homburg (DE) Medical oncologist - Camillo Porta, Bari (IT) Urologist - Evanguelos Xylinas, Paris (FR)	Virtual Room 2
<b>14:45 – 14:50</b>	<b>Abstract O1 - Determining the predictive value of a pre-operative negative PSMA PET/CT in candidates for radical prostatectomy and extended pelvic lymph node dissection</b> Dennie Meijer, Amsterdam (NL)	
<b>14:50 – 14:55</b>	<b>Abstract O2 - Are confirmatory biopsies needed in patients on active surveillance who underwent upfront MRI with possible targeted biopsy?</b> Henk Luiting, Rotterdam (NL)	
<b>14:55 – 15:00</b>	<b>Abstract O3 - Management and survival of patients with retroperitoneal recurrences following radical nephrectomy: Results from a multi-institutional international datasets</b> Michele Marchioni, Cantalice (IT)	
<b>15:00 – 15:05</b>	<b>Abstract O4 - Molecular subtypes of fully resected clear cell renal cell carcinoma are prognostic for risk of relapse and may impact adjuvant treatment</b> Eduard Roussel, Brugge (BE)	
<b>15:05 – 15:10</b>	<b>Abstract O5 - A subgroup analysis from the IMvigor130 study in patients with upper tract vs. lower tract locally advanced or metastatic urothelial carcinoma treated with atezolizumab plus platinum-based chemotherapy</b> Aristoteles Bamias, Athens (GR)	
<b>15:10 – 15:15</b>	<b>Abstract O6 - Hybrid ICG-99mTc-nanocolloid, on the road towards becoming the new standard for sentinel node biopsy in penile cancer?</b> Hielke-Martijn De Vries, Leiden (NL)	
<b>15:15 – 15:30</b>	Discussion	
<b>15:30 – 15:45</b>	<b>Industry presentation</b>	Virtual Room 2
<b>15:45 – 16:30</b>	<b>Oligometastatic disease in genito-urinary cancers</b> Chairs: Medical oncologist - Manuela Schmidinger, Vienna (AT) Urologist - Alberto Briganti, Milan (IT) Radiation oncologist - Pierre Blanchard, Villejuif (FR)	Virtual Room 1
<b>15:45 – 15:55</b>	<b>Definition and biology</b> Urologist - Henk Van Der Poel, Amsterdam (NL)	
<b>15:55 – 16:05</b>	<b>How reliable is imaging?</b> Radiologist - Harriet Thoeny, Fribourg (CH)	
<b>16:05 – 16:15</b>	<b>Regional treatment of metastasis: What for?</b> Urologist - Steven Joniau, Leuven (BE)	
<b>16:15 – 16:30</b>	Discussion	
<b>16:30 – 17:15</b>	<b>Industry session Bayer</b>	Virtual Room 2
<b>17:15 – 18:45</b>	<b>Organ preservation in challenging cases</b> Chairs: Radiation oncologist - Ananya Choudhury, Manchester (GB) Urologist - TBC Medical oncologist - Yohann Loriot, Villejuif (FR)	Virtual Room 1

**17:15 – 17:30 Active surveillance in intermediate risk prostate cancer**

17:15 – 17:20 Case presenter: Urologist - Nicola Fossati, Milan (IT)

17:20 – 17:30 Discussant: Pathologist - Mahul Amin, Memphis (US)

**17:30 – 17:45 Partial nephrectomy in T2 tumour**

17:30 – 17:35 Case presenter: Urologist - Alessandro Larcher, Milan (IT)

17:35 – 17:40 Yes: Urologist - Börje Ljungberg, Umea (SE)

17:40 – 17:45 No: Urologist - Hein Van Poppel, Leuven (BE)

**17:45 – 18:00 Kidney sparing in UTUC**

17:45 - 17:50 Case presenter: Urologist - Athanasios Dellis, Athens (GR)

17:50 – 18:00 Discussant: Urologist - Sharokh Shariat, Vienna (AT)

**18:00 - 18:15 Testis cancer**

18:00 - 18:05 Case presenter: Urologist - Andreas Hiester, Düsseldorf (DE)

18:05 - 18:15 Discussant: Urologist – Peter Albers, Dusseldorf (DE)

**18:15 - 18:30 Penile cancer**

18:15 - 18:20 Case presenter: Urologist - Ioannis Varkarakis, Athens (GR)

18:20 - 18:30 Discussant: Urological surgeon - Arie Parnham, Manchester (GB)

**18:30 - 18:45 Bladder cancer (trimodal vs cystectomy)**

18:30 - 18:35 Case presenter: Urologist - Marco Moschini, Lucerne (CH)

18:35 – 18:40 Trimodal discussant: Radiation oncologist - Ananya Choudhury, Manchester (GB)

18:40 – 18:45 Cystectomy discussant: Urologist - Morgan Rouprêt, Paris (FR)

**18:45 – 19:30 Industry session**

Virtual Room 2

**19:30 – 20:00 Take home messages and closing remarks**

Virtual Room 1

19:30 – 19:35 Pathologist - Rodolfo Montironi, Ancona (IT)

19:35 – 19:40 Radiation oncologist - Michael Pinkawa, Bonn (DE)

19:40 – 19:45 Urologist - Axel Merseburger, Lübeck (DE)

19:45 – 19:50 Radiologist - Harriet Thoeny, Fribourg (CH)

19:50 – 19:55 Medical oncologist - Jan Oldenburg, Oslo (NO)

**19:55 – 20:00 Closing remarks**

Medical oncologist - Aristotelis Bamias, Athens (GR)

Radiation oncologist - Peter Hoskin, Northwood (GB)

Urologist - Arnulf Stenzl, Tübingen (DE)